The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, ...

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...